HomeCompareGYNAF vs ABBV

GYNAF vs ABBV: Dividend Comparison 2026

GYNAF yields 2352.94% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GYNAF wins by $45519356928.60M in total portfolio value
10 years
GYNAF
GYNAF
● Live price
2352.94%
Share price
$0.09
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45519356928.70M
Annual income
$42,007,375,163,282,280.00
Full GYNAF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — GYNAF vs ABBV

📍 GYNAF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGYNAFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GYNAF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GYNAF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GYNAF
Annual income on $10K today (after 15% tax)
$200,000.00/yr
After 10yr DRIP, annual income (after tax)
$35,706,268,888,789,936.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, GYNAF beats the other by $35,706,268,888,768,880.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GYNAF + ABBV for your $10,000?

GYNAF: 50%ABBV: 50%
100% ABBV50/50100% GYNAF
Portfolio after 10yr
$22759678464.40M
Annual income
$21,003,687,581,653,524.00/yr
Blended yield
92.28%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

GYNAF
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GYNAF buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGYNAFABBV
Forward yield2352.94%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$45519356928.70M$102.3K
Annual income after 10y$42,007,375,163,282,280.00$24,771.77
Total dividends collected$45272987243.93M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GYNAF vs ABBV ($10,000, DRIP)

YearGYNAF PortfolioGYNAF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$245,994$235,294.12$11,550$430.00+$234.4KGYNAF
2$5,672,650$5,409,436.34$13,472$627.96+$5.66MGYNAF
3$122,651,200$116,581,464.56$15,906$926.08+$122.64MGYNAF
4$2,486,999,472$2,355,762,688.14$19,071$1,382.55+$2486.98MGYNAF
5$47,303,912,724$44,642,823,288.25$23,302$2,095.81+$47303.89MGYNAF
6$844,192,504,436$793,577,317,821.29$29,150$3,237.93+$844192.48MGYNAF
7$14,139,076,820,564$13,235,790,840,818.43$37,536$5,121.41+$14139076.78MGYNAF
8$222,307,787,268,425$207,178,975,070,420.90$50,079$8,338.38+$222307787.22MGYNAF
9$3,282,225,948,987,354$3,044,356,616,610,139.00$69,753$14,065.80+$3282225948.92MGYNAF
10$45,519,356,928,698,750$42,007,375,163,282,280.00$102,337$24,771.77+$45519356928.60MGYNAF

GYNAF vs ABBV: Complete Analysis 2026

GYNAFStock

Guyana Goldstrike Inc. engages in the acquisition, exploration, and development of mineral resource properties. The company holds an option agreement to acquire an interest in the Alice Arm North property, a precious metal prospect; and East Georgie property, as well as the San Diego mineral claim located in the Golden Triangle, British Columbia. The company was formerly known as Swift Resources Inc. and changed its name to Guyana Goldstrike Inc. in March 2017. Guyana Goldstrike Inc. was incorporated in 2006 and is headquartered in Vancouver, Canada.

Full GYNAF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this GYNAF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GYNAF vs SCHDGYNAF vs JEPIGYNAF vs OGYNAF vs KOGYNAF vs MAINGYNAF vs JNJGYNAF vs MRKGYNAF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.